⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Comorbidity Burden and Steroid Use in Generalized Myasthenia Gravis: A Retrospective Analysis of Medicare Fee-for-service Claims (P4-11.015)

Michael Blackowicz Shirali Pandya Daniel Basoff Aaron Carabajal-Johnson Philip Chan Nana Numapau

View Full Paper

Ask AI

Bookmark

Share

Abstract

To characterize the comorbidity burden and steroid usage patterns in Medicare fee-for-service beneficiaries with generalized myasthenia gravis (gMG) in the US.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Blackowicz et al. (2024) studied this question.

synapsesocial.com/papers/68e6fdadb6db643587677f20 https://doi.org/10.1212/wnl.0000000000205166

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Burden of glucocorticoid use in commercially insured adults with generalized myasthenia gravis in the United States: A retrospective claims-based analysisOriginal Research · 2026 · 1 citations
2Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events2024 · 19 citations
3Real-world Treatment Patterns, Discontinuation, and Treatment Switches in Patients With Generalized Myasthenia Gravis (gMG): A Retrospective Claims Analysis (P4-9.003)Cohort Study · 2026
4Unmet Needs Amongst Patients With Generalized Myasthenia Gravis in the U.S.: A Descriptive Comparison Across Two Time Periods Using the MGFA Global MG Patient Registry (P4-9.005)Original Research · 2026
5Patterns of Steroid Use and Outcomes in US Patients with Generalized Myasthenia Gravis (gMG) Receiving C5 Inhibitor Therapy (C5IT) (P10-11.011)2024